Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Robbins

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohortNeil H Segal, Sai-Hong I Ou, Ani Balmanoukian, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Nature Medicine|September 8, 2020
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trialRobert J Motzer, Paul B Robbins, Thomas Powles, et al.
The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohortNeil H Segal, Sai-Hong I Ou, Ani Balmanoukian, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Nature Medicine|September 8, 2020
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trialRobert J Motzer, Paul B Robbins, Thomas Powles, et al.
The New England Journal of Medicine|February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaRobert J Motzer, Konstantin Penkov, John Haanen, et al.
Pageof 2